File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma

TitleEvaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma
Authors
KeywordsEBV
BART microRNA
early detection
nasopharyngeal carcinoma
Issue Date2018
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal of Cancer, 2018, v. 143 n. 12, p. 3209-3217 How to Cite?
AbstractNasopharyngeal carcinoma is an Epstein–Barr Virus (EBV) associated malignancy which is highly prevalent in Southeast Asia. EBV‐related antibodies have been widely used as screening markers for early nasopharyngeal carcinoma (NPC) detection. However, due to its low positive predictive rate, it is essential to develop new biomarkers to facilitate NPC early diagnosis or triage EBV serological high‐risk individuals to improve the chance of NPC early detection. BART microRNAs, which are encoded by BamHI region of EBV, were reported to be abundant in NPC and have potential value in early diagnosis of NPC. Here, we quantified circulating level of 17 BART microRNAs in discovery stage based on previous microarray and sequencing data and, in particular, BART 2‐5p, the sole candidate whose area under curve (AUC) was higher than 0.8, has been chosen for further study. In validation stage, the sensitivity, specificity and AUC of BART 2‐5p was 93.9%, 89.8%, 0.972 (95%CI: 0.954–0.989), respectively, in Cohort 1 constituted by NPC patients and controls from Hong Kong. For validation Cohort 2 consisting of patients and controls from Guangzhou, the sensitivity, specificity and AUC was 94.2%, 83.5%, 0.959 (95%CI: 0.939–0.980), respectively. To evaluate its ability to distinguish preclinical NPC patients, we established a nested case–control study with serum samples prospectively collected from 22 NPC patients prior to their clinical diagnosis and 88 matched healthy high‐risk controls in a screening trial. The sensitivity and specificity were 90.9% and 54.5%. Collectively, EBV microRNA BART2‐5p may be a valuable biomarker for early detection of NPC.
Persistent Identifierhttp://hdl.handle.net/10722/258369
ISSN
2019 Impact Factor: 5.145
2015 SCImago Journal Rankings: 2.657
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorJIANG, C-
dc.contributor.authorCHEN, J-
dc.contributor.authorXie, S-
dc.contributor.authorZhang, L-
dc.contributor.authorXiang, Y-
dc.contributor.authorLung, M-
dc.contributor.authorKam, NW-
dc.contributor.authorKwong, DLW-
dc.contributor.authorCao, S-
dc.contributor.authorGuan, XY-
dc.date.accessioned2018-08-22T01:37:24Z-
dc.date.available2018-08-22T01:37:24Z-
dc.date.issued2018-
dc.identifier.citationInternational Journal of Cancer, 2018, v. 143 n. 12, p. 3209-3217-
dc.identifier.issn0020-7136-
dc.identifier.urihttp://hdl.handle.net/10722/258369-
dc.description.abstractNasopharyngeal carcinoma is an Epstein–Barr Virus (EBV) associated malignancy which is highly prevalent in Southeast Asia. EBV‐related antibodies have been widely used as screening markers for early nasopharyngeal carcinoma (NPC) detection. However, due to its low positive predictive rate, it is essential to develop new biomarkers to facilitate NPC early diagnosis or triage EBV serological high‐risk individuals to improve the chance of NPC early detection. BART microRNAs, which are encoded by BamHI region of EBV, were reported to be abundant in NPC and have potential value in early diagnosis of NPC. Here, we quantified circulating level of 17 BART microRNAs in discovery stage based on previous microarray and sequencing data and, in particular, BART 2‐5p, the sole candidate whose area under curve (AUC) was higher than 0.8, has been chosen for further study. In validation stage, the sensitivity, specificity and AUC of BART 2‐5p was 93.9%, 89.8%, 0.972 (95%CI: 0.954–0.989), respectively, in Cohort 1 constituted by NPC patients and controls from Hong Kong. For validation Cohort 2 consisting of patients and controls from Guangzhou, the sensitivity, specificity and AUC was 94.2%, 83.5%, 0.959 (95%CI: 0.939–0.980), respectively. To evaluate its ability to distinguish preclinical NPC patients, we established a nested case–control study with serum samples prospectively collected from 22 NPC patients prior to their clinical diagnosis and 88 matched healthy high‐risk controls in a screening trial. The sensitivity and specificity were 90.9% and 54.5%. Collectively, EBV microRNA BART2‐5p may be a valuable biomarker for early detection of NPC.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home-
dc.relation.ispartofInternational Journal of Cancer-
dc.rightsPostprint This is the peer reviewed version of the following article: [International Journal of Cancer, 2018, v. 143 n. 12, p. 3209-3217], which has been published in final form at [http://dx.doi.org/10.1002/ijc.31642]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectEBV-
dc.subjectBART microRNA-
dc.subjectearly detection-
dc.subjectnasopharyngeal carcinoma-
dc.titleEvaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma-
dc.typeArticle-
dc.identifier.emailLung, M: mlilung@hku.hk-
dc.identifier.emailKam, NW: nwkam@hku.hk-
dc.identifier.emailKwong, DLW: dlwkwong@hku.hk-
dc.identifier.emailGuan, XY: xyguan@hku.hk-
dc.identifier.authorityLung, M=rp00300-
dc.identifier.authorityKwong, DLW=rp00414-
dc.identifier.authorityGuan, XY=rp00454-
dc.description.naturepostprint-
dc.identifier.doi10.1002/ijc.31642-
dc.identifier.pmid29971780-
dc.identifier.scopuseid_2-s2.0-85056720607-
dc.identifier.hkuros286575-
dc.identifier.volume143-
dc.identifier.issue12-
dc.identifier.spage3209-
dc.identifier.epage3217-
dc.identifier.isiWOS:000451115900015-
dc.publisher.placeUnited States-
dc.identifier.issnl0020-7136-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats